健康元药业集团 九届董事会十次会议 证券代码：600380 证券简称：健康元 公告编号：临 2025-043 健康元药业集团股份有限公司 九届董事会十次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 健康元药业集团股份有限公司（以下简称：本公司）九届董事会十次会议于 2025 年 5 月 16 日（星期五）以电子邮件并电话确认的形式发出会议通知，并于 2025 年 5 月 22 日（星期四）以通讯表决形式召开。会议应参加董事九人，实际参加董事九人， 公司三名监事会成员、总裁清楚本次会议议案并无任何异议，符合《公司法》及《公 司章程》的规定。会议审议并通过如下议案： 一、审议并通过《关于控股子公司丽珠集团拟收购越南 IMP 公司股权的议案》 同意本公司控股子公司丽珠医药集团股份有限公司全资附属公司 LIAN SGP HOLDING PTE.LTD.（以下简称"LIAN SGP"）与 SK Investment Vina III Pte. Ltd.（以 下简称"SK"）、Sunrise Kim Investment ...

Group 1 - The company intends to acquire 64.81% of Imexpharm Corporation (IMP) in Vietnam for approximately 5.73 trillion VND, equivalent to about 1.587 billion RMB, which represents 10.92% of the company's latest audited net assets [2][3] - The acquisition will be executed by LIAN SGP, a wholly-owned subsidiary of the company's controlling subsidiary, Lijun Group, and will not constitute a related party transaction or a major asset restructuring as defined by relevant regulations [2][3] - The transaction has been approved by the company's board of directors and does not require shareholder approval [2][3] Group 2 - The target company, IMP, is a leading pharmaceutical enterprise in Vietnam, primarily engaged in the research, production, and sale of pharmaceuticals, including antibiotics and cardiovascular drugs, which align well with the existing product portfolio of Lijun Group [5][6] - The acquisition is expected to strengthen the company's international market presence and support its long-term strategy for sustainable development in the pharmaceutical sector [8] Group 3 - The transaction is subject to certain conditions, including regulatory approvals in Vietnam, and the company will comply with all necessary legal and regulatory requirements [3][10] - The acquisition will not involve personnel placement, land leasing, or debt restructuring, and upon completion, IMP will become a controlled subsidiary within the company's consolidated financial statements [8][9]

每经记者｜范芊芊 每经编辑｜马子卿 并购重组 健康元：丽珠集团拟15.87亿元收购越南IMP公司64.81%股权 健康元公告称，控股子公司丽珠集团之全资附属公司LIAN SGP拟以57308亿越南盾（折合人民币约 15.87亿元）收购越南上市公司IMP（Imexpharm Corporation）64.81%股份。交易完成后，标的公司将成 为健康元合并报表范围内的附属公司。 宏创控股：公司拟购买山东宏拓实业100%股权 大千生态公告称，公司股东安徽新华发行（集团）控股有限公司计划通过集中竞价、大宗交易方式减持 公司股票不超过407.16万股，不超过公司总股本的3%；副总经理王正安计划通过集中竞价方式减持公 司股票不超过41.08万股，减持比例不超过公司总股本的0.3%。 商络电子：持股5%以上股东谢丽拟减持不超过350万股 商络电子公告称，公司持股5%以上股东谢丽计划在公告披露日起15个交易日后的3个月内，通过集中竞 价交易或大宗交易方式减持其持有的不超过350万股公司股份，占剔除回购专用账户股份后公司总股本 的0.51%。 风险事项 舒泰神：公司多个在研项目属于创新型生物制品，相关在研项目正在推进中 舒泰神 ...

健康元药业集团 丽珠集团拟收购越南 IMP 公司股权的公告 证券代码：600380 证券简称：健康元 公告编号：临 2025-044 健康元药业集团股份有限公司 关于控股子公司丽珠集团拟收购越南 IMP 公司股权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●健康元药业集团股份有限公司（以下简称：本公司）控股子公司丽珠医药集 团股份有限公司（以下简称"丽珠集团"）之全资附属公司LIAN SGP HOLDING PTE.LTD.（以下简称"LIAN SGP"）拟以5,730,815,426,000越南盾（折合约为人民币 15.87亿元）收购越南上市公司Imexpharm Corporation 64.81%股份。 本次交易完成后，标的公司将成为本公司合并报表范围内的附属公司。 ●本次交易不构成关联交易，亦不构成《上市公司重大资产重组管理办法》规 定的上市公司重大资产重组。 ●本次交易已经公司九届董事会十次会议审议通过，根据《上海证券交易所股 票上市规则》等相关规定，本议案拟定事项在董事会的审议权限范围内 ...

健康元药业集团 九届董事会十次会议 证券代码：600380 证券简称：健康元 公告编号：临 2025-043 健康元药业集团股份有限公司 九届董事会十次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 健康元药业集团股份有限公司（以下简称：本公司）九届董事会十次会议于 2025 年 5 月 16 日（星期五）以电子邮件并电话确认的形式发出会议通知，并于 2025 年 5 月 22 日（星期四）以通讯表决形式召开。会议应参加董事九人，实际参加董事九人， 公司三名监事会成员、总裁清楚本次会议议案并无任何异议，符合《公司法》及《公 司章程》的规定。会议审议并通过如下议案： 同意本公司控股子公司丽珠医药集团股份有限公司全资附属公司 LIAN SGP HOLDING PTE.LTD.（以下简称"LIAN SGP"）与 SK Investment Vina III Pte. Ltd.（以 下简称"SK"）、Sunrise Kim Investment Joint Stock Company（以下简称"Sunrise"） 及 K ...

Core Insights - The MSCI report indicates a significant upward trend in ESG ratings across the Asia-Pacific region, with Chinese companies showing remarkable improvement [1][3] - In 2024, 26% of the 758 Chinese companies assessed received upgraded ratings, marking a historical high, with AA and AAA rated companies increasing to 8.9% from 1.4% in 2020 [1][3] - The Shanghai Stock Exchange companies have demonstrated substantial achievements in ESG practices, with 1,068 companies disclosing ESG reports, achieving a disclosure rate of 63%, a record high [1] Group 1 - A total of 306 Shanghai Stock Exchange companies were included in the MSCI ESG ratings, with 90 companies receiving upgrades, and 9 companies jumping 2 to 3 rating levels [3] - Eight companies from the Shanghai Stock Exchange achieved AAA ratings, including four banks and four other firms, indicating their global leadership in ESG performance [3] - The number of companies rated A and above increased from 37 to 49 among the 296 companies continuously rated by MSCI for two years, reflecting overall improvement in ESG performance [3] Group 2 - The MSCI Asia-Pacific Sustainable and Climate Products Advisor highlighted that companies prioritizing ESG practices tend to have better financial performance and risk resilience over time [3][4] - Companies that rethink their sustainable development strategies in areas like supply chain management and governance can uncover new opportunities for growth [4] - The proactive embrace of ESG principles by Shanghai Stock Exchange companies not only demonstrates their commitment to social responsibility but also revitalizes their development and sets a benchmark for enterprises globally [4]

MSCI最新发布的《2024年亚太区ESG评级领导者与上调报告》报告，系统评估了亚太13个市场ESG评 级的趋势与行业分布。中国市场在本轮评级周期中展现出显著跃升势头，是区域内最具动能的市场之 一。 在MSCI对758家中国公司ESG评级评估中，2024年26%公司获得评级上调，创下了历史新高，评级为 AA与AAA的企业占比升至8.9%(2020年为1.4%)。政策推动、治理提升与绿色技术创新共同驱动评级跃 升，反映中国企业正逐步从响应者转向践行者。 以沪市公司为例，2024年沪市主板1068家公司单独披露ESG报告，披露率达63%，创下历史新高。沪市 公司的实践表明，将ESG要素深度融入技术创新、管理体系和产业转型，更能培育差异化的竞争优势。 沪市主板公司 ESG评级排名进步明显 数据显示，共有306家沪市主板公司被纳入MSCI ESG评级，其中90家公司在最新一次评级中获得等级 提升，9家公司评级"跳升"2至3个等级，如新奥天然气股份有限公司、海信视像（600060）科技股份有 限公司、健康元（600380）药业集团股份有限公司等；8家公司评级获得AAA级，除4家银行(建设银 行、民生银行、招商银行、兴业 ...

Summary of Key Points Core Viewpoint - The company held a performance and cash dividend briefing for the fiscal year 2024 and the first quarter of 2025, emphasizing its optimistic outlook for the pharmaceutical industry driven by multiple favorable factors [1][2]. Company Performance and Strategy - The company is focusing on innovative drugs as its core development direction, particularly in the respiratory disease treatment area, with over ten innovative drug projects in the pipeline [3][5]. - The company has successfully reserved over twenty innovative drugs covering various important therapeutic areas, with several entering critical clinical phases [3][5]. - The company aims to enhance its operational efficiency and resource utilization to achieve sustainable growth [6]. Industry Outlook - The pharmaceutical industry is expected to experience medium to high-speed growth, with significant improvements in innovation capabilities and modernization of the industrial chain by 2025 [5]. - The industry reported a total revenue of 25,298.5 billion yuan in 2024, with a slight decrease in total profit by 1.1% year-on-year due to temporary adjustments [5]. Financial Performance - The company reported a steady performance in the first quarter of 2025, despite facing some pressure from industry policy adjustments [9]. - The company's R&D expenses for 2024 are projected to be around 400 million yuan, reflecting a year-on-year increase of approximately 30% [8]. Market Development - The company is actively working on market expansion for its newly approved products, such as the Tobramycin inhalation solution and the Salmeterol/Fluticasone inhalation powder, aiming for significant growth contributions in the coming years [6][9].

健康元药业集团 关于 2024 年度暨 2025 年第一季度业绩暨现金分红说明会召开情况的公告 证券代码：600380 证券简称：健康元 公告编号：临 2025-042 健康元药业集团股份有限公司关于 2024 年度暨 2025 年第一季度业绩暨现金分红说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 健康元药业集团股份有限公司（以下简称：公司）于 2025 年 05 月 12 日（星期一）下 午 15:00-17:00 在上海证券交易所上证路演中心（网址：http://roadshow.sseinfo.com/），以 视频与网络文字互动方式召开了 2024 年度暨 2025 年第一季度业绩暨现金分红说明会，针 对公司 2024 年度及 2025 年第一季度的经营成果及财务指标等具体情况与投资者进行互动 交流和沟通，在信息披露允许的范围内就投资者普遍关注的问题进行现场回复，现就有关 情况公告如下： 一、本次说明会召开情况 2025 年 05 月 12 日（星期一）下午 15:00-17:00，公司在上海证券 ...

Core Viewpoint - Health元药业's subsidiary, Lijuzhu Microball Technology Co., Ltd., has received approval for the injectable Aripiprazole microspheres, which is expected to enhance medication adherence and reduce relapse rates in adult schizophrenia patients [1][2]. Group 1: Drug Registration Details - The drug is named Aripiprazole Microspheres for Injection, with a dosage of 350mg [1]. - The registration certificate was issued by the National Medical Products Administration, confirming compliance with drug registration requirements [1]. - The drug is classified as a chemical drug of category 2.2 and is produced by Zhuhai Lijuzhu Microball Technology Co., Ltd. [1]. Group 2: Drug Development and Market Context - The injectable Aripiprazole microspheres were submitted for market approval in September 2023, with the acceptance number CXHS2300080 [2]. - This long-acting formulation is designed for monthly administration, which can improve patient compliance and reduce both economic and social burdens [2]. - As of the announcement date, Lijuzhu Microball is the only company with production approval for Aripiprazole microspheres, with no other similar products available globally [2]. Group 3: Market Potential - The estimated terminal sales value of antipsychotic drugs in China for 2024 is approximately RMB 6.048 billion, with long-acting formulations accounting for around RMB 1.418 billion [2].